8-K Announcements
6Material company update
Dec 9, 2025·SEC
Material company update
Dec 3, 2025·SEC
Material company update
Oct 9, 2025·SEC
Akero Therapeutics, Inc.(AKRO)Earnings, Financials & Key Ratios
AKRO•NASDAQ
$54.65
Price updated Jun 20, 2026
AboutAkero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$285M-65.1%
- Net Income-$252M-66.1%
- EPS (Diluted)-3.75-29.8%
- ROE-39.22%-11.4%
AKRO Price & Volume
Akero Therapeutics, Inc. (AKRO) stock price & volume — 10-year historical chart
Loading chart...
Intensifying Clinical R&D Drives Significant Cash Burn
Investment Thesis • Updated 2025Q3
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Clinical trial execution dependency
Key Thesis Takeaways
- Akero Therapeutics remains a high-risk, clinical-stage biotechnology firm whose valuation is entirely contingent upon the successful development of its MASH therapeutic pipeline.
- While the company maintains a clean balance sheet with a debt-to-equity ratio of 0.00, the lack of revenue and an escalating quarterly operating loss of $90.2 million in 2025Q3 necessitate ongoing reliance on capital markets.
- Investors should monitor the company's ability to reach critical Phase 3 milestones, as the current cash runway has tightened to $176.0 million, potentially exposing shareholders to further dilution.
Verdict Logic
Negative: The company's lack of revenue and the rapid depletion of cash reserves from $623.9 million in 2024Q1 to $176.0 million in 2025Q3 present a substantial risk of future equity dilution.
AKRO Growth Metrics
Akero Therapeutics, Inc. (AKRO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.44%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM0.27%
Return on Capital
10 Years-167.81%
5 Years-42.85%
3 Years-42.06%
Last Year-42.37%
AKRO Recent Earnings
Akero Therapeutics, Inc. (AKRO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q4 2025Latest
Nov 7, 2025Metric
Actual
Est
EPS
$0.99-5.3%
$0.94
Rev
—
—
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.86+11.3%
$0.97
Rev
—
—
Q2 2025
May 12, 2025Metric
Actual
Est
EPS
$0.90+189.1%
$1.01
Rev
—
—
Q1 2025
Feb 28, 2025Metric
Actual
Est
EPS
$0.99-1.0%
$0.98
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 7, 2025 | $0.99vs $0.94-5.3% | — |
| Q3 2025 | Aug 8, 2025 | $0.86vs $0.97+11.3% | — |
| Q2 2025 | May 12, 2025 | $0.90vs $1.01+189.1% | — |
| Q1 2025 | Feb 28, 2025 | $0.99vs $0.98-1.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Akero Therapeutics, Inc. (AKRO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $54.65 | $4.5B | -14.57 | — | — | -39.22% | — | |
| $545.36 | $12.57B | -42.44 | 432.05% | -27.32% | -50.15% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $50.92 | $3.1B | -27.83 | — | — | -21.04% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $56.63 | $3.26B | -23.60 | — | — | -15.14% | — |
Compare AKRO vs Peers
Akero Therapeutics, Inc. (AKRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AKRO SEC Filings & Documents
Akero Therapeutics, Inc. (AKRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when AKRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AKRO Frequently Asked Questions
Akero Therapeutics, Inc. (AKRO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is AKRO profitable?
Akero Therapeutics, Inc. (AKRO) reported a net loss of $292.8M for fiscal year 2024.
Dividend & Returns
What is AKRO's return on equity?
Akero Therapeutics, Inc. (AKRO) has a return on equity (ROE) of -39.2%. Negative ROE indicates the company is unprofitable.
What is Akero Therapeutics, Inc.'s free cash flow?
Akero Therapeutics, Inc. (AKRO) had negative free cash flow of $250.2M in fiscal year 2024, likely due to heavy capital investments.